Real-World Prescribing of Renal and Cardiovascular Protective Drugs in Patients With Type 2 Diabetes and Chronic Kidney Disease: Analysis of Data From a Western Australian Quaternary Hospital
In patients admitted to the hospital with T2D and CKD, one-quarter were prescribed an SGLT2 inhibitor and/or a GLP-1 agonist at discharge. Further studies are required to identify barriers and enablers to prescribing these drugs.
Authors
- Bridget A. McFadden (ORCID: https://orcid.org/0000-0002-8626-9531)
- Harish Puttagunta
- Sharon Ho
- P. Gerry Fegan (ORCID: https://orcid.org/0000-0001-8100-6209)
- Andrew D. Johnson (ORCID: https://orcid.org/0000-0001-6369-5178)
- Girish Dwivedi (ORCID: https://orcid.org/0000-0003-0717-740X)
- N. Lan (ORCID: https://orcid.org/0000-0002-7222-7314)
- Ramyasuda Swaminathan
- R. Stephen Gillett
- Phillip Shedden
Institutions
- Government of Western Australia (AU)
- Harry Perkins Institute of Medical Research (AU)
- Fiona Stanley Hospital (AU)
Publication Details
- Journal
- Heart Lung and Circulation
- Published
- 2025-09-05
- DOI
- https://doi.org/10.1016/j.hlc.2025.07.007
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59